Title
Category
Credits
Event date
Cost
Podcast - Ironing Out the Data: Iron Deficiency in Heart Failure
  • CMHC
  • 0.50 ACPE Pharmacy
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC
  • 0.50 Participation
$0.00
CardioNerds Cofounder Dr. Amit Goyal, Chair of the CardioNerds Heart Failure Committee Dr. Jenna Skowronski, and Episode FIT Lead Dr. Shazli Khan discuss iron deficiency and its impact on heart failure with Dr. Robert Mentz, Chief of Heart Failure at Duke University and principal investigator of the HEART-FID trial. In this case-based discussion, they cover the diagnostic criteria of iron deficiency in heart failure, epidemiology, and strengths and limitations of different iron formulations.
Optimizing the Recognition and Treatment of Chronic Kidney Disease in Patients with Type 2 Diabetes: What Primary Care Clinicians Need to Know
  • CMHC
  • 1.25 ACPE Pharmacy
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 ANCC
  • 1.25 Participation
$0.00
Welcome to our micro-module webcast on the challenges of managing chronic kidney disease (CKD) and diabetes. After diagnosis, slowing CKD progression in type 2 diabetes (T2D) continues to pose a major challenge. Although new therapies, such as sodium-glucose cotransporter-2 (SGLT-2) inhibitors, have emerged, residual morbidity and mortality persist. Additional strategies are required to slow kidney disease progression, especially targeting inflammation and fibrosis.
Dietary Strategies for Reversing Type 2 Diabetes: Advances, Perspectives, and Expert Discussions
  • CMHC
  • 4.00 Participation
$0.00
Dr. Ronald M. Krauss, MD, Professor of Medicine at UCSF and Adjunct Professor of Nutritional Sciences at UC Berkeley, and Nina Teicholz, PhD, author and science journalist, co-organized this course on Dietary Approaches to Reversing Type 2 Diabetes. The course is offered as a legacy to the late Dr. Sarah Hallberg, a pioneer in the research and promotion of putting type 2 (T2) diabetes into remission—or “reversal” of the disease, as she preferred to describe the process of restoring average blood sugar (A1c) to normal levels while eliminating the need for all or most medications.
At the Forefront of Care for Patients with Worsening Heart Failure: New and Emerging Treatment Options
  • CMHC
  • 1.25 ACPE Pharmacy
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 ANCC
  • 1.25 Participation
$0.00
Welcome to our webcast on worsening heart failure. Heart failure remains one of the most challenging conditions to manage, with worsening heart failure being a critical area where suboptimal outcomes persist. While foundational therapies such as beta-blockers, ACE inhibitors, mineralocorticoid receptor antagonists, and ARNIs remain integral to heart failure management, advances in our understanding of heart failure pathophysiology have opened the door to newer, innovative therapeutic options, such as SGLT-2i, sCG stimulators and SGLT1/2 inhibitors.
Psoriasis in Skin of Color Unplugged: Addressing the Barriers to Patient Care and Relief
  • LivDerm
  • TME
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Participation
$0.00
Various gaps in the management of psoriasis patients with skin of color (SOC) persist due to a lack of training on SOC and inherent barriers to care. As a result, psoriasis patients with SOC are often misdiagnosed, experience more severe disease, and experience more disease burden. Recent clinical trial data supports the need for nuanced care when treating psoriasis patients with SOC using systemic agents. It is important that clinicians are able to identify treatment barriers and develop strategies to address these barriers and personalize care.
Scratching the Surface of BTK Inhibition for Chronic Spontaneous Urticaria: Beyond Skin Deep
  • LivDerm
  • TME
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Participation
$0.00
BTK inhibitors have demonstrated great promise for addressing various treatment challenges for chronic urticaria patients by improving symptom control and more effective targeting of disease pathways.
Addressing the Cardiometabolic Risk Continuum in MASH: What Clinicians Need to Know
  • CMHC
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 CDE
  • 1.00 Participation
$0.00
Metabolic dysfunction-associated steatohepatitis (MASH) is a complex condition rooted in metabolic disturbances and often coexists with obesity, prediabetes, type 2 diabetes, and cardiovascular disease. Stemming from metabolic dysfunction-associated steatotic liver disease (MASLD), MASH is closely linked to cardiometabolic risk factors and pre-existing cardiovascular conditions. MASH is a gradually advancing and often asymptomatic liver disease that necessitates early detection and diagnosis.
Clinical Brief: Advancements in Dyslipidemia Treatments and ASCVD Risk Reduction for High-Risk Individuals
  • CMHC
  • 0.50 ACPE Pharmacy
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC
  • 0.50 CDE
  • 0.50 Participation
$0.00
This clinical brief was developed from a presentation at the 19th CMHC Annual Congress held from October 17-19, 2024 in Boston, MA. The session, “Evolving Therapies in Dyslipidemia and ASCVD Risk Reduction: Putting It All Together in High-Risk Patients,” was presented by Dr. Pamela B. Morris, Professor of Medicine, Cardiology from The Medical University of South Carolina, Charleston, SC, supported by an educational grant from Esperion Therapeutics.

Pages